ENPP-2 Overview
Molecule Name
Ectonucleotide pyrophosphatase/phosphodiesterase 2
Synonyms
ENPP-2,E-NPP 2,Autotaxin,LysoPLD,ATX,PDNP2,ATX-X,NPP2,PD-IALPHA
Drug Development Progress
Drugs in Clinical Trials9
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
EC:3.1.4.39，ATX，Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2，Phosphodiesterase I/Nucleotide Pyrophosphatase 2，Plasma Lysophospholipase D，Autotaxin-T，EC 3.1.4.39，PD-IALPHA，ATX-X，NPP2，E-NPP 2，Autotaxin，ENPP2，PDNP2，Ectonucleotide Pyrophosphatase/Phosphodiesterase 2，Extracellular Lysophospholipase D，LysoPLD
Background
Autotaxin also known as ectonucleotide pyrophosphatase / phosphodiesterase family member 2 (E-NPP 2 or ENPP2), Extracellular lysophospholipase D (LysoPLD), Autotaxin (ATX or ATX-X), which belongs to the nucleotide pyrophosphatase / phosphodiesterase family. ENPP2 contains two SMB (somatomedin-B) domains. ENPP2 hydrolyzes lysophospholipids to produce lysophosphatidic acid (LPA) in extracellular fluids. ENPP2 can act on sphingosylphosphphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility. ENPP2 stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein.
ENPP-2 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BBT-877 | BBT-877 | Phase 2 Clinical | Legochem | Idiopathic Pulmonary Fibrosis | Details |
| Cambritaxestat | CRT-0273750; IOA-289 | Phase 2 Clinical | Cancer Research Technology, Merck & Co | Pancreatic Neoplasms; Solid tumours | Details |
| HRS-9813 | HRS-9813; HRS9813 | Phase 2 Clinical | Guangdong Hengrui Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details |
| HW-021199 | HW-021199 | Phase 2 Clinical | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Humanwell Puracap (Likang) Pharmaceuticals Co Ltd | Idiopathic Pulmonary Fibrosis | Details |
| HNC664 | HNC664; HNC-664 | Phase 1 Clinical | Guangzhou Henovcom Bioscience Co Ltd | Idiopathic Pulmonary Fibrosis; Pancreatic Neoplasms | Details |
| Cudetaxestat | PAT-409; BLD-0409 | Phase 1 Clinical | Blade Therapeutics Inc | Idiopathic Pulmonary Fibrosis; Liver Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| NXC-680 | NXC-680 | Phase 1 Clinical | Nextgen Bioscience Inc | Idiopathic Pulmonary Fibrosis | Details |
| HNC-1058 | HNC-1058 | Phase 1 Clinical | Guangzhou Henovcom Bioscience Co Ltd | Idiopathic Pulmonary Fibrosis | Details |
| FTP-198 | FTP-198 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Idiopathic Pulmonary Fibrosis | Details |